About Us

The company finalizes a test for Alzheimer’s disease based on two biomarkers detection, which is carried out on blood samples.

The company has obtained some first clinical results, which are one of the most reliable in sensitivity and specificity, for a blood diagnostic test for Alzheimer’s disease.

Alzheimer’s disease is a heavy social and economical burden for developed countries and will soon become as problematic for rapidly growing economies. Since this disease is related to aging its occurrence increases with life expectancy. The initial phase of the disease is generally slow leading to progressive cognitive decline. Using biological tests for diagnosis before pathological clinical symptoms would support an early treatment, which consequently would be more efficient. This represents one of the most promising tracks against Alzheimer’s disease.